Dr. Sartor Explains the ARTISAN Trial
In a recent presentation, Dr. Oliver Sartor highlighted Lead-212 (Pb-212) as a promising next step in precision radioligand therapy for metastatic castration-resistant prostate cancer. Developed by the same Oslo-based team that introduced Radium-223, Lead-212 is being studied in the ARTISAN (AB001) trial and represents a significant evolution in alpha-emitting radiopharmaceuticals. Its defining features are a […]
